摘要
目的从生物利用性角度评价含朱砂中成药中汞的潜在健康风险。方法火焰原子吸收法（FAAS）测定含朱砂中成药总汞含量,体外消化透析法模拟人体胃肠消化,氢化物发生—原子荧光光谱法（HG-AFS）检测得到含朱砂中成药中汞生物利用性相关数据。结果 6种常用含朱砂中成药在人工胃液中汞溶出率在0.14%~1.96%范围内,小肠阶段汞可接受率为0.003 8%~0.011 7%。基于汞在人体的半衰期和蓄积中毒量,反推导出含朱砂中成药中汞元素的安全阈值为每人每天0.099 mg。结论综合考虑6种常用含朱砂中成药的汞含量水平、服用剂量、服用频次等,说明口服含朱砂中成药引起汞暴露的安全风险性较低。
Objective To introduce mercury bioaccessibility for risk assessment of Chinese patent medicines containing cinnabar.Methods Total mercury from Chinese patent medicines containing cinnabar was determined by FAAS.In vitro digestion and dialysis method was adopted to simulate the conditions of gastric compartment and intestinal compartment and dialysate fractions were collected and quantified by the means of HG-AFS.Results In the gastric compartment,the solubility of mercury from six common Chinese patent medicines containing cinnabar ranged from 0.14%~1.96%;in the intestinal compartment,mercury bioaccessibility（0.003 8%~0.011 7%） was found for all the samples.The toxic threshold level of mercury was 0.099 mg/（person·day） for the case of Chinese patent medicines containing cinnabar on the basis of available data on mercury（cumulative toxic dose and half-life） in the body.Conclusion Taking into consideration on mercury level and intake of Chinese patent medicines containing cinnabar,the potential health risk seems to be low.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2010年第11期2749-2751,共3页
Lishizhen Medicine and Materia Medica Research
基金
海南省自然科学基金(No.200802)
关键词
生物利用性
体外消化透析法
含朱砂中成药
安全阈值
汞
Bioavailability
In vitro digestion and dialysis method
Chinese patent medicines containing cinnabar
Toxic threshold
Mercury
